

## CLINICAL RESEARCH EXECUTIVE GOVERNANCE ENDORSEMENT

Dear Prof Rowe,

**OUTCOME OF REVIEW: Endorsement - subject to conditions**

**RE: "Protocol No. 233AS303A: Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation", Ref: MQCRG2021038**

Thank you for submitting your research project for clinical research governance review by the MQ Health Clinical Research Executive (CRE).

The CRE has determined that your project is feasible and aligned with the MQ Health strategic priorities and have initially endorsed your project. Initial endorsement is **valid for one (1) year** from the date of this letter.

Please note, this is not your final approval. Final governance authorisation is **subject to and conditional upon you presenting the following:**

- Final ethics approval from MQ HREC
- Evidence that all relevant approvals and agreements are in place (e.g. Deputy Vice-Chancellor Research sign off).

Your final MQ Health governance authorisation letter will be provided upon presentation of the required final approvals and sign offs mentioned above. Once you have received your final governance authorisation letter you can commence your research.

To help ensure you use the appropriate MQ Health affiliation in research publications, please refer to our [MQ Health Guide to bylines in research publications](#).

If you have any questions, please contact the Clinical Research Team: [clinical.research@mqhealth.org.au](mailto:clinical.research@mqhealth.org.au).

**Important note:** *The design and other scientific aspects of the proposed project have not been reviewed by the CRE, as these areas are considered in detail during the subsequent scientific and ethics review.*

Prof Roger Chung on behalf of the MQ Health Clinical Research Executive.



Date: 21 June 2021